Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
- 28 Downloads
Aim of the study was to assess impact of pretherapeutic FDG-PET/CT metabolic parameters on response to chemoradiotherapy (CRT) and survival in locally advanced cervical cancer (LACC) patients without paraaortic lymph node involvement.
LACC patients treated with CRT without macrometastatic involvement after paraaortic surgical staging were included. All patients had received at least 45 Gy radiotherapy and five cycles of platinum-based chemotherapy. High-risk histologies were excluded. Two senior nuclear physician experts in gynaecologic oncology reviewed all PET/CT exams, and extracted tumor SUVmax, MTV, and TLG (standardized uptake value, metabolic tumor volume, and total lesion glycolysis respectively). Response to CRT was assessed with a pelvic MRI done after 45 Gy. Medical charts were reviewed for clinical, pathology, and survival data.
Ninety-three patients were included in the study. The overall survival (OS) rates at 2 and 5 years were 83.0% [95%CI: 72.5–89.8] and 71.2% [57.5–81.2] respectively. The RFS rates at 2 and 5 years were 72.5% [61.5–80.9] and 64.4% [52.3–74.2] respectively. Higher cervical SUVmax and TLG were significantly associated with poor response to CRT. In multivariate analysis, cervical SUVmax was the main predictive factor for OS.
Cervical tumor SUVmax was demonstrated to be a non-invasive prognostic biomarker for response to treatment and survival in LACC patients without paraaortic involvement. SUVmax and other PET/CT metabolic parameters require further prospective investigation to help tailoring of local treatment.
KeywordsCervix cancer SUV Prognosis Chemoradiotherapy FDG-PET/CT
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors of this article have no relevant relationships that could be perceived as a real or apparent conflict of interest.
- 1.Global Cancer Observatory, OMS. Estimated number of incident cases, worldwide (top 10 cancer sites) in 2012. Disponible sur http://gco.iarc.fr/today/online-analysis-multi-bars?mode=cancer&mode_population=continents&population=900&sex=2&cancer=16&type=0&statistic=0&prevalence=0&color_palette=default.
- 9.Sapienza LG, Gomes MJL, Calsavara VF, Leitao MM Jr, Baiocchi G. Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer ? A systematic review and meta-analysis of randomized clinical trials. Gynecol Oncol. 2017;144(2):312–317. https://doi.org/10.1016/j.ygyno.2016.11.044.
- 10.Oh D, Lee JE, Huh J, Park W, Nam H, Choi Y. Prognostic significance of tumor response as assessed by sequential 18 F-Fluorodeoxyglucose-positron emission tomography / computed tomography during concurrent chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013;87(3):549–54. https://doi.org/10.1016/j.ijrobp.2013.07.009.CrossRefPubMedGoogle Scholar
- 18.Roman-Jimenez G, Ospina JD, Leseur J, et al. Investigating the contribution of pre- and per-treatment 18F-FDG PET-CT segmentation methodologies for post-treatment tumor recurrence prediction in cervical cancer. IRBM. 2013;34(4-5):274–7. https://doi.org/10.1016/j.irbm.2013.09.002.CrossRefGoogle Scholar
- 19.Boellaard R, Delgado-Bolton R, WJG O, et al. FDG PET / CT : FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.
- 21.Chung HH, Cheon GJ, Kim JW, Park NH, Song YS. Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix. Eur J Nucl Med Mol Imaging. 2017;44(11):1862–1869. https://doi.org/10.1007/s00259-017-3729-x.CrossRefPubMedGoogle Scholar
- 22.Sarker A, Im H-J, Cheon GJ, Chung HH, Kang KW, Chung J-K, et al. Prognostic implications of the SUVmax of primary tumors and metastatic lymph node measured by 18F-FDG PET in patients with uterine cervical cancer. A meta-analysis. Clin Nucl Med. 2016;41(1):34–40. https://doi.org/10.1097/RLU.0000000000001049.CrossRefPubMedGoogle Scholar
- 23.Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol. 2010;119(1):81–6. https://doi.org/10.1016/j.ygyno.2010.04.020.CrossRefPubMedGoogle Scholar
- 29.Scarsbrook A, Vaidyanathan S, Chowdhury F, Swift S, Cooper R, Patel C. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017;44:581–8. https://doi.org/10.1007/s00259-016-3537-8.CrossRefPubMedGoogle Scholar
- 30.Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2012. https://doi.org/10.1016/j.ijrobp.2012.02.056.
- 31.Ueno Y, Lisbona R, Tamada T, Alaref A, Sugimura K, Reinhold C. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer. Br J Radiol. 2017;90(1075):20170035.CrossRefGoogle Scholar
- 32.Yoo J, Choi JY, Moon SH, Bae DS, Kim B. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using F-Fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer. 2012;22(7):1226–33. https://doi.org/10.1097/IGC.0b013e318260a905.CrossRefPubMedGoogle Scholar
- 33.Chong GO, Jeong SY, Park S, Lee YH, Lee S. Comparison of the prognostic value of F-18 pet metabolic parameters of primary tumors and regional lymph nodes in patients with locally advanced cervical cancer who are treated with concurrent chemoradiotherapy. PLoS One. 2015:10(9):e0137743. https://doi.org/10.1371/journal.pone.0137743.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Akkas BE, Demirel BB, Dizman A, Vural GU. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer? Ann Nucl Med. 2013;27(8):756–63. https://doi.org/10.1007/s12149-013-0745-1.CrossRefPubMedGoogle Scholar
- 38.Onal C, Reyhan M, Parlak C, Guler OC, Oymak E. Prognostic value of pretreatment F-18-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy. Int J Gynecol Cancer. 2013;23(6):1104–10. https://doi.org/10.1097/IGC.0b013e3182989483.CrossRefPubMedGoogle Scholar
- 41.Pan L, Cheng J, Zhou M. The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol. 2012;138(2):239–46. https://doi.org/10.1007/s00432-011-1092-z.
- 42.Cima S, Perrone AM, Castellucci P, et al. Prognostic impact of pretreatment fluorodeoxyglucose positron emission tomography/computed tomography SUVmax in patients with locally advanced cervical cancer. Int J Gynecol Cancer. 2018;28(3):575–580. https://doi.org/10.1097/IGC.0000000000001207 CrossRefPubMedGoogle Scholar
- 45.Lucia F, Visvikis D, Desseroit M, et al. Prediction of outcome using pretreatment 18 F-FDG PET / CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017;45(5):768–786. https://doi.org/10.1007/s00259-017-3898-7.CrossRefPubMedGoogle Scholar
- 46.Henriksson EVA, Kjellen E, Wahlberg P, Ohlsson T, Wennerberg J, Brun EVA. 2-Deoxy-2- [ 18 F ] Fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Res. 2007;2160:2155–9.Google Scholar